{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 37,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a stepped process diagram to illustrate dose escalation cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/13",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.075,
        "w": 0.3,
        "x": 0.628,
        "y": 0.375
      },
      "kind": "diagram",
      "text": "MAD 1 SC, MAD 2 SC",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3a78b10-c788-4a52-8be7-935e795240a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.061,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "SAD 1 SC, SAD 2 SC, SAD 3 SC, SAD 4 IV",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be09e90b-5698-420b-b998-4b039c7effc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.42,
        "x": 0.048,
        "y": 0.635
      },
      "kind": "legend",
      "text": "Expected interim YE2024 readout to include 2-3 SAD cohorts and is sufficient to answer key objectives with PK modeling",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bbae25b-75c7-4880-bbc1-14b203a217c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.553,
        "y": 0.72
      },
      "kind": "list",
      "text": "Multiple ascending dose cohorts: Healthy volunteers, N=8/cohort (3:1 randomization), Two doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cad7323-0a56-4f14-afc1-886a96086681",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.033,
        "y": 0.72
      },
      "kind": "list",
      "text": "Single-ascending dose cohorts: Healthy volunteers, N=8/cohort (3:1 randomization)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ff5f031-2ba3-4785-8cf7-50fcd9acfdc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.56,
        "x": 0.025,
        "y": 0.03
      },
      "kind": "title",
      "text": "SPY001 Phase 1 clinical trial design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9048aca1-b943-465d-892b-ef3ae71c0f83",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "b7ab41ba-8438-4b98-bff4-9202b42b06cb",
      "evidence": "Standardized representation of SAD/MAD cohort escalation",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563",
      "evidence": "The solution section presents a clear 'why' for Spyre's approach",
      "position": 1,
      "objective": "Why does Spyre's approach make sense?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}